CD133: An emerging prognostic factor and therapeutic target in colorectal cancer

Morteza Akbari,Navid Shomali,Afsaneh Faraji,Dariush Shanehbandi,Milad Asadi,Ahad Mokhtarzadeh,Aliakbar Shabani,Behzad Baradaran
DOI: https://doi.org/10.1002/cbin.11243
Abstract:Colorectal cancer (CRC) is one of the leading causes of death worldwide. Recently, the role of cancer stem cells (CSCs) has been highlighted as a crucial emerging factor in chemoresistance, cancer relapse, and metastasis. CD133 is a surface marker of CSCs and has been argued to have prognostic and therapeutic values in CRC along with its related pathways such as Wnt, Notch, and hedgehog. Several studies have successfully applied targeted therapies against CD133 in CRC models namely bispecific antibodies (BiAbs) and anti-Wnt and notch pathways agents. These studies have yielded initial promising results in this regard. However, none of the therapeutics have been used in the clinical setting and their efficacy and adverse effects profile are yet to be elucidated. This review aims to gather the old and most recent data on the prognostic and therapeutic values of CD133 and CD133-targeted therapies in CRC.
What problem does this paper attempt to address?